FDA grants QIDP designation to Armata's AP-SA02 for S. aureus bacteremia

Armata Pharmaceuticals, Inc.

• AP-SA02 receives QIDP for intravenous adjunct treatment of complicated MSSA/MRSA bacteremia.
• QIDP provides five-year Hatch-Waxman market exclusivity extension and eligibility for Fast Track.
• CEO Dr. Deborah Birx says Phase 3 superiority study planned to start in H2 2026.
• Company intends to submit a request for Fast Track Designation for AP-SA02 to FDA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.